Drug Profile


Alternative Names: Desvenlafaxine hydrochloride; Desvenlafaxine SR; Desvenlafaxine succinate; Desvenlafaxine succinate sustained release; Desvenlafaxine sustained-release; DVS-233; DVS-233 SR; DVS-SR; O-desmethylvenlafaxine; Pristiq; WY-45233

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Jiangsu Hansoh Pharmaceutical; Pfizer; Wyeth
  • Class Antidepressants; Cyclohexanols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder; Vasomotor symptoms
  • Discontinued Fibromyalgia; Neuropathic pain

Most Recent Events

  • 30 Apr 2016 Pfizer completes a phase III trial for Major depressive disorder (In children, In adolescents) in USA and Chile (NCT01371708)
  • 01 Oct 2015 Pfizer completes an extension phase III trial in Major depressive disorder (In children, In adolescents) in USA and Mexico (PO) (NCT01371721)
  • 01 Jul 2015 First generic equivalent approved in USA for Major depressive disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top